June 1, 2023
Biosenta Inc. ceases negotiations with Voran Group Ventures Ltd.
CALGARY, Alberta, May 31, 2023 (GLOBE NEWSWIRE) — Biosenta Inc. ( “Biosenta”) (CSE: ZRO) announces that, further to its news…
Pharmaceuticals, Biotechnology and Life Sciences
CALGARY, Alberta, May 31, 2023 (GLOBE NEWSWIRE) — Biosenta Inc. ( “Biosenta”) (CSE: ZRO) announces that, further to its news…
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 31, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the publication…
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader…
MISSISSAUGA, Ontario, May 31, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce…
Up to an Additional $46.2 Million Available Through Warrant Exercise Led by Novalis LifeSciences LLC with participation from Northpond Ventures,…
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the…
BOULDER, Colo., May 31, 2023 (GLOBE NEWSWIRE) — Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused…
Plans to Exit Existing U.S. hemp-derived CBD Operations Intends to Launch Lord Jones® Brand in the Canadian Adult-use Market in…
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology…
HB-200 in combination with pembrolizumab doubled the objective response rate of 1st-line pembrolizumab for patients with recurrent/metastatic head and neck…